Boehringer Ingelheim | PCDS Wales | Diabetes on the Net

Diabetes on the Net is intended for healthcare professionals

Company Profile

BOEHRINGER INGELHEIM IN THE UK
We are Boehringer Ingelheim – a different kind of pharmaceutical company.
Family-owned. Purpose-led. Innovation-driven: We serve mankind by aiming to improve health for people and animals.


Established in 1885, we have always been independent and family-owned, meaning we have the freedom to pursue our purpose – identifying health challenges of the future, and targeting areas of need where we can do the most good.

By working collaboratively, we aim to accelerate the delivery of medical breakthroughs to improve the lives of patients now, and for generations to come.

In the UK we do this through scientific innovation – taking on the biggest challenges in medicine. We invest in sustainable healthcare – planning for the long term alongside the NHS and our partners in the veterinary world. We support digital transformation by partnering with innovators to drive healthcare improvements.

More information can be found at www.boehringer-ingelheim.co.uk

This resource page and the materials included have been organised and funded by  Boehringer Ingelheim

Click here to access Trajenta (linagliptin) prescribing information

Resources

Play Video

Kevin Fernando, GPwSI in Diabetes and Medical Education, North Berwick

PC-GB-102519

PC-GB-102838

Date of prep: September 2020

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.